Cornerstone Therapeutics (CRTX) Receives Warning Letter From FDA Nov 20, 2009 03:42PM

Cornerstone Therapeutics Inc. (Nasdaq: CRTX) had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce. Cornerstone is preparing an appropriate response to the FDA.

Cornerstone has not sold any Deconsal CT products since July 2009 and has not sold any Deconsal DM products since January 2009. Net revenues from the sales of the Deconsal products in 2009 year to date are $173,498. Cornerstone does not intend to manufacture, or have manufactured, any further lots of this product.

[SM]


Pfizer (PFE) Gets Okay for Bipolar Treatment Geodon from U.S. FDA Nov 20, 2009 01:22PM

Pfizer (NYSEL PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.

Geodon is also FDA-approved for the treatment of acute manic and mixed episodes associated with bipolar disorder, with or without psychotic features, and for the treatment of schizophrenia. Since the FDA approval of Geodon in February 2001, nearly 2 million adult patients have been treated with this important therapy.

Bipolar disorder, which affects approximately 5.7 million adults in the United States, is a debilitating, chronic condition that requires lifelong treatment and management. More than 90 percent of patients with bipolar disorder have recurring mood episodes, making it important to establish a long-term treatment plan to help prevent recurrence and stabilize mood. The recurrence of mood episodes associated with bipolar disorder can have a devastating impact on patients' lives, and the disease is associated with high rates of disability.


Intuitive Surgical (ISRG) Receives Japanese Approval for da Vinci Nov 20, 2009 01:21PM

Intuitive Surgical, Inc. (Nasdaq: ISRG) announced that it has received regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) to allow marketing of its da Vinci S System in Japan.

Commenting on the announcement, Gary Guthart, President and COO of Intuitive Surgical, said, "We are pleased with the Ministry of Health's decision to grant Shonin approval for the da Vinci S Surgical System. This approval has been a long process for Intuitive, and we are happy to be one step closer to bringing our products to market in Japan. Our focus will now shift toward satisfying the trade and importation requirements necessary for commercialization and to obtain appropriate reimbursement for da Vinci procedures in Japan."


Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment Nov 20, 2009 08:36AM

Dendreon Corporation (NASDAQ: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

The FDA considers this to be a complete, Class 2 Resubmission following the action letter the company received in 2007. The BLA includes data from the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC. The resubmission also contains the remaining information requested by the FDA pertaining to chemistry, manufacturing and controls section of the BLA for PROVENGE.

If approved by the FDA, PROVENGE would represent the first product in a new therapeutic class known as active cellular immunotherapies.


Boston Scientific (BSX) Receives 510(k) Clearance and CE Mark on WallFlex Nov 20, 2009 08:33AM

Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer.

The WallFlex® Partially Covered Esophageal Stent was cleared by the FDA and received CE Mark in 2008. Both stents -- along with the complete WallFlex Stent family of self-expanding metal stents (SEMS) -- will be available for hands-on demonstration at the GASTRO 2009 conference, which is being held November 21-25 in London.


More FDA

View Older Stories

Nov 20, 2009 07:32AM Covidien (COV) Announces FDA Extends Review of NDA for Exalgo
Nov 19, 2009 04:40PM Matrixx Initiatives (MTXX) Files Response with FDA on Zicam
Nov 19, 2009 11:17AM Salix (SLXP) December volatility at 56, January at 68, April at 73 into PDUFA
Nov 18, 2009 11:36AM UnitedHealth's (UNH) Prescription Solutions Releases Study Finding No Significant Differences Between Ezetimibe/Simvastatin and Statin Alone
Nov 18, 2009 11:06AM BSD Medical (BSDM) Provides Update on FDA's Review of Company's BSD-2000 Hyperthermia System
Nov 18, 2009 09:01AM Medtronic (MDT) Receives FDA Warning Letter Following Inspection of Its Minnesota Facility
Nov 17, 2009 04:55PM VIVUS (VVUS) Will Announces Phase 3 Results of Avanafil Before The Market Opens
Nov 17, 2009 08:59AM NeurogesX (NGSX) Higher On FDA Approval of Qutenza
Nov 17, 2009 08:45AM Merck (MRK) Announces Results of COZAAR Study; Increased Dose Reduced Death or Hospitalization from Heart Failure
Nov 17, 2009 08:45AM InterMune (ITMN) Modifies On-Going Phase 2b Study of ITMN-191
Nov 17, 2009 07:31AM Discovery Laboratories (DSCO) Submits Propsed Protocol for Surfaxin Clinical to U.S. FDA
Nov 16, 2009 02:49PM Kinetic Concepts (KCI) Losses Bid To Halt Sales of Smith & Nephew Wound Kits - Bloomberg
Nov 16, 2009 02:21PM Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
Nov 16, 2009 11:37AM ODAC to Review Using OSI Pharma's (OSIP) Tarceva as First-Line Therapy for Patients with Advanced Non-Small Cell Lung Cancer
Nov 16, 2009 09:28AM NovaDel Pharma (NVD) to Enter into Exclusive License and Distribution Agreement with ECR Pharma for ZolpiMist
Nov 16, 2009 09:19AM Genzyme (GENZ) Receives FDA Complete Response Letter Regarding Application to Market Lumizyme
Nov 16, 2009 09:11AM Biotech Movers: SPEX, NABI, ALKS Up; PARD, CRXX Down
Nov 16, 2009 08:31AM Par Pharma (PRX) Receives Final U.S. FDA Approval for Tramadol ER Doses
Nov 16, 2009 08:06AM Alkermes (ALKS) Reports Positive Preliminary Results from Phase 3 Trial of Naltrexone
Nov 16, 2009 07:42AM Covidien (COV) Announces Neuromed Representatives Discuss Pending NDA for ExalgoTM
Nov 16, 2009 07:33AM CombinatoRx (CRXX) Receives FDA Feedback on NDA for Exalgo ER Tablets
Nov 16, 2009 07:24AM Human Genome (HGSI) Receives U.S. FDA Response Letter for Anthrax Treatment Raxibacumab
Nov 16, 2009 07:16AM Poniard Pharma (PARD) SPEAR Phase III of Picoplatin Did Not Meet Survival Endpoint
Nov 16, 2009 06:45AM GLAXO (GSK) and Nabi BioPharma (NABI) Announce Option and Licensing Agreement for NicVAX
Nov 13, 2009 07:20PM Genzyme's (GENZ) Quality Control Detects Foreign Particles in Five Enzyme Replacement Products; Issues Letters to U.S. Healthcare Providers
Nov 13, 2009 02:16PM Goldman Sachs Says FDA News on Genzyme (GENZ) is a "Significant Negative Surprise"
Nov 13, 2009 12:43PM Deutsche Bank Says Genzyme (GENZ) FDA Warning May Not Be a Big Deal
Nov 13, 2009 12:04PM BioMarin (BMRN) Responds to News of Contamination at Genzyme (GENZ) Plant; Says Aldurazyme, Naglazyme Won't Be Impacted
Nov 13, 2009 11:47AM FDA Says Genzyme's (GENZ) Rare Disease Drugs May Be Contaminated -Bloomberg
Nov 13, 2009 07:37AM FDA Extends Cadence Pharmaceuticals (CADX) PDUFA Date by Three Months
Nov 12, 2009 10:16AM Cadence Pharmaceuticals (CADX) Up Ahead of Tomorrow's PDUFA Date
Nov 11, 2009 12:16PM Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
Nov 10, 2009 04:28PM Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
Nov 10, 2009 03:27PM Mylan (MYL) Gets FDA Ok for Generic Prevacid
Nov 9, 2009 03:08PM Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
Nov 9, 2009 10:27AM Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
Nov 9, 2009 09:26AM Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
Nov 9, 2009 09:21AM Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
Nov 9, 2009 08:44AM Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
Nov 5, 2009 09:09AM TapImmune (TPIV) In License Agreement with Crucell (CRXL)
Nov 5, 2009 07:16AM Poniard Pharma (PARD) option volume and prices elevated into data
Nov 5, 2009 07:07AM BioCryst (BCRX) Receives Order for 10K Courses of Peramivir from U.S. for H1N1, Worth $22.5M
Nov 4, 2009 02:14PM BioCryst (BCRX) Jumps Higher After Canceling Conference Appearance
Nov 4, 2009 11:11AM Merriman Curhan Positive On Celldex Therapeutics (CLDX) After Results and Ahead of Events
Nov 4, 2009 09:07AM BioCryst (BCRX) Partner In Japan Files NDA for Peramivir
Nov 4, 2009 08:59AM RXi Pharmaceuticals (RXII) Data to Be Presented at Conference Today
Nov 4, 2009 08:34AM GenVec (GNVC) Up After FDA Grants Orphan Drug Designation for TNFerade
Nov 3, 2009 11:53AM InterMune (ITMN) Higher Following INFORM-1 Trial Data
Nov 2, 2009 11:05AM Human Genome (HGSI) Second Successful Trial Sets Stage For Benlysta Approval
Nov 2, 2009 10:40AM Cardium (CXM) Plans File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL
View Older Stories